154 related articles for article (PubMed ID: 38332225)
21. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
22. Investigating cellular similarities and differences between upper tract urothelial carcinoma and bladder urothelial carcinoma using single-cell sequencing.
Zhang Q; Wang C; Qin M; Ye Y; Mo Y; Meng Q; Yang G; Feng G; Lin R; Xian S; Wei J; Chen S; Wang S; Mo Z
Front Immunol; 2024; 15():1298087. PubMed ID: 38903524
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
24. Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma.
Liu MA; Li JW; Runcie K
Curr Oncol Rep; 2024 May; 26(5):496-503. PubMed ID: 38602581
[TBL] [Abstract][Full Text] [Related]
25. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.
Ehdaie B; Theodorescu D
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1103-10. PubMed ID: 18588455
[TBL] [Abstract][Full Text] [Related]
26. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates.
Solomon JP; Hansel DE
Adv Anat Pathol; 2015 Mar; 22(2):102-12. PubMed ID: 25664945
[TBL] [Abstract][Full Text] [Related]
28. p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma.
Piaton E; Carré C; Advenier AS; Decaussin-Petrucci M; Mège-Lechevallier F; Lantier P; Granier G; Ruffion A
Cancer Cytopathol; 2014 Mar; 122(3):211-20. PubMed ID: 24302621
[TBL] [Abstract][Full Text] [Related]
29. Variants and new entities of bladder cancer.
Lopez-Beltran A; Henriques V; Montironi R; Cimadamore A; Raspollini MR; Cheng L
Histopathology; 2019 Jan; 74(1):77-96. PubMed ID: 30565299
[TBL] [Abstract][Full Text] [Related]
30. Diminution of Primary Cilia in the Stromal Cells at the Tumor-stromal Interface Correlates With an Aggressive Tumor Biology in the Urothelial Carcinoma of the Urinary Bladder.
Kapaganti VK; Purkait S; Nayak P; Biswas D; Mohamedali R; Adhya AK; Mitra S
Appl Immunohistochem Mol Morphol; 2024 Mar; 32(3):130-136. PubMed ID: 38374714
[TBL] [Abstract][Full Text] [Related]
31. The landscape of immunotherapy in metastatic urothelial carcinoma.
Teo MY; Iyer G
Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
[TBL] [Abstract][Full Text] [Related]
32. Molecular Pathology of Urothelial Carcinoma.
Al-Ahmadie H; Netto GJ
Clin Lab Med; 2024 Jun; 44(2):181-198. PubMed ID: 38821640
[TBL] [Abstract][Full Text] [Related]
33. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
Fujiwara Y; Karol AB; Joshi H; Reford E; Izadmehr S; Doroshow DB; Galsky MD
Crit Rev Oncol Hematol; 2024 May; 197():104352. PubMed ID: 38614269
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review.
Sanguedolce F; Russo D; Calò B; Cindolo L; Carrieri G; Cormio L
Pathol Res Pract; 2019 Jun; 215(6):152413. PubMed ID: 30987832
[TBL] [Abstract][Full Text] [Related]
35. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma.
Kawashima A; Kanazawa T; Jingushi K; Kato T; Ujike T; Nagahara A; Fujita K; Morimoto-Okazawa A; Iwahori K; Uemura M; Imamura R; Wada H; Nonomura N
Clin Genitourin Cancer; 2019 Apr; 17(2):114-124. PubMed ID: 30555025
[TBL] [Abstract][Full Text] [Related]
37. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
[No Abstract] [Full Text] [Related]
38. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.
Sahu D; Lotan Y; Wittmann B; Neri B; Hansel DE
Cancer Med; 2017 Sep; 6(9):2106-2120. PubMed ID: 28766915
[TBL] [Abstract][Full Text] [Related]
39. Stromal and vascular invasion in an human in vitro bladder cancer model.
Booth C; Harnden P; Trejdosiewicz LK; Scriven S; Selby PJ; Southgate J
Lab Invest; 1997 Jun; 76(6):843-57. PubMed ID: 9194860
[TBL] [Abstract][Full Text] [Related]
40. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
